The epidemiology of neuroblastoma suggests that prenatal exposures may be important etiologic factors in this disease. The authors describe the role of maternal health status and prenatal medication usage and risk of neuroblastoma. This retrospective study was based on completed interviews with 183 histologically confirmed neuroblastoma cases aged 0-14 years diagnosed among residents of New York State (excluding New York City) between 1976 and 1987. Controls were matched to cases on year of birth and race and were drawn from the New York State live birth certificate registry. Interviews were satisfactorily completed with 85% of the cases and 87% of controls. Significantly elevated odds ratios were noted for vaginal infections during pregnancy (odds ratio (OR) = 2.2, 95% confidence interval (Cl) 1.2-4.0), medical treatments for vaginal infection during pregnancy (OR = 2.4, 95% Cl 1.2-4.9), and any reported use of sex hormones during pregnancy (OR = 3.0, 95% Cl 1.3-6.9). Point estimates for any hormone use suggested elevated risk among male offspring (OR = 4.4, 95% Cl 1.5-13.3). Among the individual exposures comprising any hormone use, only hormone use related to infertility was observed to be significant (OR = 10.4, 95% Cl 1.2-89.9). A protective effect was noted for self-reported vitamin use (OR = 0.28, 95% Cl 0.03-0.69). Although it is not possible to presume a specific role for prenatal hormone exposure as initiator or promoter, these findings lend support to an association between prenatal hormone exposure and risk of neuroblastoma. Am J Epidemiol
Neuroblastoma is one of the most common tumors of childhood. However, given the relative rarity of childhood cancer in general, the infrequency of neuroblastoma has precluded the development of large epidemiologic data sets. Average annual incidence rates of neuroblastoma among children aged 0-14 years in New York State for the period 1976-1987 are 0.99 per 100,000 males and 0.93 per 100,000 females (unpublished data, New York State Department of Health, Cancer Registry). The inability of any one research center to amass a sufficient sample size has prevented the systematic investigation of risk factors for this disease. Neuroblastoma is the most commonly diagnosed tumor during infancy; approximately half of all cases are diagnosed in the first 2 years of life. Prenatal exposures may be thought to play a major role in the etiology of neuroblastoma given the early age at diagnosis. The current study was undertaken to explore the relation between a myriad of intrauterine exposures and risk of neuroblastoma in the affected offspring.
The focus of this manuscript is on prenatal exposures and, in particular, the role of maternal health status and use of medications during pregnancy relative to risk of neuroblastoma.
MATERIALS AND METHODS
Cases (n -219) included in this study were derived from the New York State Cancer Registry provided they met the following inclusion criteria: 1) diagnosed with a neuroblastoma between January 1, 1976 and December 31, 1987; 2) less than 15 years of age at time of diagnosis; and 3) parent(s) were residents of New York State. Cases or controls with amended or sealed (adopted) birth certificates were excluded from the study due to inherent difficulties associated with incomplete records or issues pertaining to confidentiality. Hospital records were obtained for all cases to verify histologic diagnosis of neuroblastoma and to obtain staging information.
The live birth certificate registry maintained by the New York State Department of Health was used as the sampling frame for selection of controls. Controls were frequency matched to cases on year of birth at a ratio of approximately 2:1. Matching on year of birth also ensured equivalent periods of recall. Mean time from birth of the index child to date of interview was found to be 12.6 (standard deviation (SD) 4.7) for cases and 13.3 (SD 4.7) for controls. Due to the limited number of cases among nonwhites (n = 20), only cases born to white mothers were included in the study. Parents of controls also were required to be residents of New York State.
Letters were first sent to the attending physician of cases listed on the New York State Cancer Registry Report Card or the medical record. This letter explained the purpose of the study and requested permission to contact the index case mother for enrollment into the study. Letters of introduction were mailed to mothers of cases and controls to request their participation. One of four trained interviewers contacted mothers by telephone. The telephone interview comprised five sections of maternal variables: 1) gestational characteristics of infants; 2) gravid drug use and medical history; 3) behavioral and occupational factors; 4) pregnancy and lactation histories; and 5) sociodemographic information. In regard to gravid drug use and medical history, mothers were presented with a list of medical conditions and asked if they had been told by a physician that they had any of these conditions/illnesses during their index pregnancy. If mothers responded in the affirmative, they were asked whether they had taken any medication for the condition and, if so, the type and duration of use during pregnancy. No further attempts were made to validate negative responses. Interviews lasted approximately one hour and were edited for completion and accuracy prior to data entry.
A review of hospital records showed that three patients had been incorrectly reported to the New York State Cancer Registry as neuroblastoma cases. Maternal telephone interviews were completed for 85 percent (183/216) of children with neuroblastoma. Interviews were not obtained for a variety of reasons, including unpublished phone numbers (n = 15, 45.5 percent), refusal of mothers to participate in the interview (n = 14,42.4 percent), and physician recommendation that the parents not be contacted for an interview (n = 4, 12.1 percent). Similarly, telephone interviews were completed for 87 percent of control mothers (372/428). Reasons for not interviewing control mothers included unpublished phone numbers (n = 24, 43 percent), maternal refusals (n = 20, 36 percent), and inability to locate the mother (n = 12, 21 percent).
Descriptive and analytic statistics were performed using SPSS software (1) . Crude odds ratios and 95 percent confidence intervals were obtained for selected factors and risk of neuroblastoma. Given that the controls were frequency matched to cases, unconditional logistic regression analysis was used to estimate odds ratios and 95 percent confidence intervals.
RESULTS
The analysis is based on completed interviews with 183 case mothers and 372 control mothers. A sociodemographic description of the study sample is provided in table 1. Cases were similar to controls with respect to sex and year of birth. The median age at diagnosis for cases was 18 months. Mothers of cases were similar to mothers of controls with regard to age. Mean gravidity and parity status of mothers did not vary by infant's case or control status, 2.4 and 2.4 for gravidity and 2.0 and 2.1 for parity, respectively. Mothers were most commonly primiparous at delivery of the index infant, i.e., 48 percent of cases and 42 percent of controls. Parental educational attainments were comparable between the two groups. Table 2 presents data on maternal health history. The majority of mothers did not report any diseases or adverse health conditions during pregnancy. A significantly elevated odds ratio was noted for vaginal infection during the index pregnancy (odds ratio (OR) = 2.2, 95 percent confidence interval (CI) 1.2-4.0). This risk persisted for mothers who received medications for this condition while pregnant with the index child (OR = 2.4, 95 percent CI 1.2-4.9). In terms of chronic conditions, no significant associations were observed for diabetes mellitus, epilepsy, coronary heart disease, kidney disease, hypertension, or previous cancer.
Prenatal drug history data are presented in table 3 along with unadjusted odds ratios and corresponding confidence intervals. One drug history of particular interest in this study was that of hormonal exposure. Hormonal exposure was classified as positive if mothers reported hormonal treatment for infertility, to control vaginal bleeding during pregnancy, or to prevent miscarriage. A significantly elevated odds ratio of 3.0 (95 percent CI 1.3-6.9) was observed for any reported use of sex hormones during pregnancy. This level of risk remained even after adjustment for gender using unconditional logistic regression. Of the individual exposures comprising this measure, only hormone use related to infertility was noted to be significant (OR = Breslow-Day chi-square test of homogeneity was performed to determine if risk was homogeneous across gender; results were not found to be significant {p > 0.05). Hormone use related to infertility approached significance where risk for males so exposed was 8.4 (95 percent CI 0.9-76.5). Only one female case (but no female control) was so exposed. Hormone exposure did not appear to influence neuroblastoma risk based on age at diagnosis. Risk of neuroblastoma for infants diagnosed prior to age 18 months was observed to be 1.4 (95 percent CI 0.5-4.2). However, risk for male children diagnosed earlier in life approached significance (OR = 3.0, 95 percent CI 0.7-12.2); no increased risk was noted for females (OR = 0.3, 95 percent CI 0.03-2.8). When assessing the independent effects of gender and age and risk of neuroblastoma, gender appeared to confer the greatest effect. However, small cell sizes resulting from stratification by gender and age precluded any further meaningful interpretation.
Self-reported vitamin use reflected a significant protective effect on risk of neuroblastoma (OR = 0.5, 95 percent CI 0.3-0.7). Conversely, risk of neuroblastoma in children whose mothers reported never having taken vitamins during pregnancy was 2.2 (95 percent CI 1.4-3.3). Vitamin use data need to be interpreted cautiously given that data are based on responses to an open-ended question where mothers were asked whether their doctor had prescribed any other medications during their index pregnancies. Sixtyone mothers of cases and 211 mothers of controls reported vitamin use during pregnancy in response to this open-ended question. The majority of mothers taking vitamins began in their first trimester (94 percent in both mothers of cases and controls). Duration of vitamin use did not differ between the two groups of mothers.
As previously indicated, medical records of cases were obtained to confirm histologic diagnosis and to confirm staging information. Staging was found to distribute as follows: stage I, 13 percent; stage II, 11 percent; stage in, 17 percent; stage IV, 39 percent; stage FV-S, 4 percent; and not specified, 16 percent (note-stage IV-S denotes disseminated disease characterized by enhanced survival and high rates of spontaneous regression). Analyses of stage by age (18 months), and by in utero hormone use and vitamin use did not yield significant results (data not shown).
DISCUSSION
In utero exposure to sex hormones has previously been reported to be teratogenic among exposed fetuses. Previous authors have reported an increased risk of congenital anomalies for infants exposed in utero to sex hormones, including transposition of the great vessels (2), congenital heart anomalies (3, 4), and hypospadia (5-7).
In addition to thalidomide (a non-sex hormone drug), diethylstilbestrol (DES) is one of the most widely recognized human teratogens. In utero exposure to DES is associated with a significantly increased risk of urogenital anomalies and adenocarcinoma of the vagina among exposed daughters, and of urogenital anomalies and, possibly, of testicular cancer in exposed male offspring (8) .
Of all hormones, the sex hormones are considered the most potent carcinogens, possibly exerting their carcinogenic effect by increasing the rate of cell division (9) . By increasing the mitotic rates in target organs, sex hormones increase the mutation rate per unit time (10) . Sex hormones are thought to act more as promoters or cocarcinogens than as initiators. One exception is in utero exposure. Fetal exposure to sex hormones may result in the initiation of cancer as evident by fetal exposure to DES and subsequent development of clear cell adenocarcinoma of the vagina (11).
Kramer et al. (12) first reported an association between in utero exposure to sex hormones and increased risk of neuroblastoma. A matched case-control study of 104 neuroblastoma cases diagnosed between 1970-1979 was used for assessing the relation between medical history and drug usage during the index pregnancy. Several in utero drug exposures conferred an increased risk of neuroblastoma (in descending order): diuretics (OR = 5.75), neurally active drugs (OR = 2.83), sex hormones (OR = 2.25), and antinauseants (OR = 1.74). Bleeding during pregnancy was the most frequently cited reason for taking the hormone.
Schwartzbaum (13) (14) reviewed the histories of 24 cases of neuroblastoma in relation to maternal use of sex hormones during pregnancy. Four of eight (50 percent) cases of neuroblastoma diagnosed under one year of age were either exposed to hormones at the time of conception or early during pregnancy. The authors speculate that hormonal exposures require further study in relation to neuroblastoma. It is also of interest to note that three of the four cases described were male infants. While no conclusions can be drawn from this limited case series study involving one hospital, these preliminary findings suggest that male offspring may be more vulnerable to the potentially carcinogenic effects of sex hormones.
In the current study, we observed a significant threefold increase likelihood of neuroblastoma for infants exposed in utero to sex hormones. The magnitude of effect found in the present study is higher than in previous studies, although the confidence intervals overlap. Reasons for hormonal use during pregnancy were provided by all mothers of exposed cases (n = 14) and controls (n -10). Reasons for hormonal use among cases included (in descending order): infertility {n = 5); maintain pregnancy (n = 5); bleeding (n = 4); and prior history of miscarriage (n = 2). The distribution of reasons for use of sex hormones during pregnancy was similar in our study and that of Kramer et al. (12) . In fact, our risk may be underestimated because we did not collect information on oral contraceptive usage. This is a limitation of the current study which needs to be addressed in future investigations. Kramer et al. (11) reported that the mothers of three cases and the mother of one control took oral contraceptives before realizing they were pregnant. Schwartzbaum (13) reported a risk of 1.2 (95 percent CI 0.6-2.3) for neuroblastoma among children with in utero sex hormone exposure (14 mothers). However, this latter study used other childhood cancer cases as controls and may have underestimated the magnitude of effect. Also, mothers of both cases and controls who were interviewed were observed to be different from those who were not interviewed in relation to several key variables. In utero exposure to sex hormones may elevate risk toward other cancers; however, this is speculative and requires further investigation. Kushner and Helson (15) relate a case-report of a child with neuroblastoma whose mother had a history of hormone injections to reverse amenorrhea associated with the use of oral contraceptives. They speculate that genetic effects result in diagnosis within the first year of life whereas diagnosis thereafter may be attributed to "random" mutation.
There are other considerations that need to be taken into account when interpreting our findings and those of previous authors. The biologic framework for this study assumes in utero administration of sex hormones and other drugs are absorbed by the maternal bloodstream and transmitted to the developing embryo/fetus via the placenta. Of particular concern is whether the mother's disease or health status, which necessitates the need for the drug in the first place, may be the reason for the increased risk of neuroblastoma. Our study was unable to separate out the disease from the treatment effect. Given that we had no "healthy" women such as those using oral contraceptives, coupled with small sample sizes for specific therapeutic indications, we were unable to further assess a treatment versus a disease effect. Thus, it may be premature to assert a drug effect without consideration of a possible health effect.
A second limitation of our study is the use of a retrospective approach for the ascertainment of drug exposure. Recall bias may account for the differences in self-reported drug usage by infant status. At least two studies have reported that recall bias is less problematic for women who take drugs for a longer rather than a shorter period of time (16) , or if a closed-ended approach is used for ascertainment (17) . In the present study, we ascertained drug usage specific to pregnancy using a closed-ended format (save for vitamin use that was open-ended). A significant protective effect for vitamin consumption (OR = 0.5, 95 percent CI 0.3-0.7) was observed. However, the manner in which these data were collected necessitates caution in the interpretation of this finding. There may be differential selective recall between mothers of cases and controls with mothers of cases less apt to recall "positive" experiences such as vitamin use. Similarly, recall bias cannot be totally excluded given that mothers of cases may be more likely to recall and report drug usage with purported adverse effects such as sex hormones. While it might be argued that the protective effect observed for prenatal vitamin use and the increased risk noted for hormones may reflect recall bias, this appears less likely given that other drugs or medical conditions did not show an increased risk for neuroblastoma. Future studies should employ more conventional closed-ended questioning. Periconceptional consumption of multiple vitamins and/or folk acid has been well documented as reducing the risk of neural tube defects (18, 19) . Therefore, it is possible that multiple vitamins with folic acid may also exert a protective effect for neuroblastoma. Another inherent limitation of case-control studies is that of chance observation. It is conceivable that multiple comparisons may have resulted in our observed findings. As such, careful investigation of these findings is urged. Finally, controls were selected from the New York State Live Birth Registry and, therefore, have a live birth certificate filed in New York State. Not all cases, however, were born in New York State, although the majority (94 percent) clearly were. Unfortunately, place of birth is not recorded by the New York State Cancer Registry. The potential exists that cases bom to mothers residing outside of New York State may have different in utero exposures to vitamins and drugs due to regional differences in prescribing patterns.
To our knowledge, the present study represents the largest case-control study of neuroblastoma reported to date. The high interview response rate lends some credence to the generalizability of our findings. The sizable numbers of case and control mothers interviewed increased the statistical power of this study and enabled the detection of subtle risk differences.
Our findings coupled with those of previous authors suggest that in utero exposure to sex hormones may increase the likelihood of neuroblastoma in offspring. Whether these hormones act as initiators or as promoters remains to be determined. Whatever the mechanism^), the weight of evidence suggests that in utero and periconceptional hormonal exposure may be both teratogenic and carcinogenic. Additional study is warranted to determine the role of timing and duration of use of specific sex hormones in relation to risk of neuroblastoma.
